Hytrin Related Published Studies
Well-designed clinical trials related to Hytrin (Terazosin)
Terazosin therapy for patients with female lower urinary tract symptoms: a randomized, double-blind, placebo controlled trial. [2008.04]
Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. [2007.03.05]
More effects of extracorporeal magnetic innervation and terazosin therapy than terazosin therapy alone for non-inflammatory chronic pelvic pain syndrome: a pilot study. [2006]
Comparative evaluation of Prostina and terazosin in the treatment of benign prostatic hyperplasia. [2005.02]
Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. [2004.11]
Terazosin and doxazosin in the treatment of BPH: results of a randomized study with crossover in non-responders. [2004]
Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. [2003.02]
[Effects of terazosine and atenolol on serum lipids in essential hypertension] [2002.09]
[A randomized comparative study assessing once versus twice a day treatment of benign prostatic hyperplasia with terazosin] [2001.02]
[The efficacy and safety of terazosin and tamsulosin in patients with urinary disturbance accompanying prostatic hypertrophy] [2001.01]
Use of terazosine in patients with chronic pelvic pain syndrome and evaluation by prostatitis symptom score index. [2001]
The relationship between terazosin dose and blood pressure response in hypertensive patients. [2000.10]
Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. BPH Medical Therapy Study Group. Benign prostatic hyperplasia. [2000.06]
[Efficiency and tolerance of terazosine in ambulatory patients with benign prostatic hypertrophy: comparative randomized and double-blind trial versus alfuzosin. The MG Terazosine Group] [2000.04]
A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients. [2000.04]
The mechanism of adverse events associated with terazosin: an analysis of the Veterans Affairs cooperative study. [2000.04]
Terazosine and tamsulosin in non bacterial prostatitis: a randomized placebo-controlled study. [1999.12]
A comparison of the antagonistic activities of tamsulosin and terazosin against human vascular alpha1-adrenoceptors. [1999.07]
Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications. [1999.07]
Effect of finasteride and/or terazosin on serum PSA: results of VA Cooperative Study #359. [1999.06.01]
Effects of a 3-month treatment with terazosin on fasting and postprandial glucose and lipid metabolism in type 2 diabetic patients with hypertension. [1999.04]
Differential vascular alpha1-adrenoceptor antagonism by tamsulosin and terazosin. [1999.01]
Pharmacokinetic interaction between finasteride and terazosin, but not finasteride and doxazosin. [1998.11]
Terazosin in benign prostatic hyperplasia: effects on blood pressure in normotensive and hypertensive men. [1998.09]
Effects of oral and intravenous terazosin and head-up tilt on blood pressure responses in patients with hypertension. [1998.06]
Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics. [1998.01]
Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. [1998]
A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. [1998]
Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. [1997.10]
Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo-controlled study with terazosin. HYCAT Investigator Group. Hytrin Community Assessment Trial. [1997.10]
Terazosin blockade of nicotine-induced skin flap necrosis in the rat. [1997.08]
Alpha 2-agonist versus alpha 1-antagonist in mild-to-moderate hypertension: comparison of transdermal clonidine and terazosin monotherapies. [1997.01]
Assessment of the pharmacokinetic-pharmacodynamic interaction between terazosin and finasteride. [1996.12]
The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. [1996.08.22]
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. [1996.03]
The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. [1996.02]
The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. [1996.02]
The international terazosin trial: a multicentre study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. The ITT Group. [1996]
Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms. [1995.07]
Combined terazosin and verapamil therapy in essential hypertension. Hemodynamic and pharmacokinetic interactions. [1995.02]
Terazosin and doxazosin in normotensive men with symptomatic prostatism: a pilot study to determine the effect of dosing regimen on efficacy and safety. [1995]
Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. [1994.07]
[Pressure and metabolic effects of terazosin in essential hypertension] [1994.06]
[The effects of terazosin hydrochloride and buflomedil in patients with hemicrania without aura] [1994.04]
Use of terazosin in prostatodynia and validation of a symptom score questionnaire. [1994.04]
Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group. [1993.09]
Comparison of the effects of terazosin and enalapril on laboratory stress testing blood pressure in patients with essential hypertension. [1993.05]
A comparison of the effects of the selective peripheral alpha 1-blocker terazosin with the selective beta 1-blocker atenolol on blood pressure, exercise performance and the lipid profile in mild-to-moderate essential hypertension. [1992.12]
Use of terazosin in the medical treatment of benign prostatic hyperplasia: experience in Italy. [1992.11]
Terazosin in the treatment of benign prostatic hyperplasia: the United States experience. [1992.11]
Terazosin in the treatment of benign prostatic hyperplasia: a multicentre, placebo-controlled trial. [1992.11]
Placebo-controlled study of terazosin in the treatment of benign prostatic hyperplasia with 2-year follow-up. [1992.11]
A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. [1992.11]
Double-blind placebo-controlled trial of terazosin effect on blood pressure and urinary output of dopamine in hypertensive patients. [1992.09]
Comparison of antihypertensive and lipid actions of terazosin and atenolol in essential hypertension. [1992.06]
Antihypertensive and metabolic effects of concomitant administration of terazosin and methyclothiazide for the treatment of essential hypertension. [1992.04]
The safety and efficacy of terazosin in the treatment of essential hypertension in blacks. [1991.09]
Antihypertensive dose-response relationships: studies with the selective alpha 1-blocking agent terazosin. [1991.09]
Efficacy of once-a-day terazosin in benign prostatic hyperplasia: a randomized, double-blind placebo-controlled clinical trial. [1990]
The effects of terazosin and methyclothiazide on blood pressure and serum lipids. [1989.04]
Concomitant administration of terazosin and atenolol for the treatment of essential hypertension. [1988.03]
Well-designed clinical trials possibly related to Hytrin (Terazosin)
Role of alpha1-blockers in chronic prostatitis syndromes. [2008.03]
[Comparison of different drugs on the treatment of benign prostate hyperplasia] [2007.07.15]
LC-MS determination and relative bioavailability of doxazosin mesylate tablets in healthy Chinese male volunteers. [2007.02.19]
The comparison and efficacy of 3 different alpha1-adrenergic blockers for distal ureteral stones. [2005.06]
[Serum nitric oxide and D-dimer before and after administering antihypertensive drugs in essential hypertension] [2003.08]
Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy. [2002.10]
[Treatment of external RF hyperthermia combining with alpha 1-adrenergic receptor blocker for patients with prostatodynia and chronic non-bacterial prostatitis] [2002]
Targeted transurethral microwave thermotherapy versus alpha-blockade in benign prostatic hyperplasia: outcomes at 18 months. [2001.01]
Prospective randomized comparison of high energy transurethral microwave thermotherapy versus alpha-blocker treatment of patients with benign prostatic hyperplasia. [1999.01]
Comparative efficacies of a calcium antagonist and an alpha1 blocker in elderly hypertensive patients with stroke. [1998.10]
The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. [1998.10]
Treatment of idiopathic oligozoospermia with an alpha-blocker: a placebo-controlled double-blind trial. [1997.09]
Beneficial effect of alpha-blocker on hemorheology in patients with essential hypertension. [1997.08]
Alpha-1 blockade pharmacotherapy in primitive psychogenic premature ejaculation resistant to psychotherapy. [1995]
Other research related to Hytrin (Terazosin)
Combined use of melatonin and terazosin restores bladder contractility in rabbits with partial outlet obstruction. [2008.08]
Impacts of the quinazoline-based alpha1-antagonist, terazosin, and of the sulfonamide derivative, tamsulosin, on serum prostate-specific antigen and prostate volume. [2008.06]
Acute generalized exanthematous pustulosis caused by terazosin hydrochloride. [2008.04]
Pharmacokinetic and pharmacodynamic modelling of arterial haemodynamic effects of terazosin in healthy volunteers. [2008]
High-dose terazosin therapy (5mg) in Korean patients with lower urinary tract symptoms with or without concomitant hypertension: a prospective, open-label study. [2007.12.31]
New-onset priapism associated with ingestion of terazosin in an otherwise healthy man. [2007.11]
Pharmacokinetic and pharmacodynamic consequences of inhibition of terazosin metabolism via CYP3A1 and/or 3A2 by DA-8159, an erectogenic, in rats. [2007.05]
Effects of branded versus generic terazosin hydrochloride in adults with benign prostatic hyperplasia: a randomized, open-label, crossover study in Taiwan. [2007.04]
Cardio-protective role of terazosin is possibly mediated through alteration in thyroid function. [2006.12.03]
The effect of terazosin on functional bladder outlet obstruction in women: a pilot study. [2006.10]
Efficacy of terazosin as a facilitator agent for expulsion of the lower ureteral stones. [2006.06]
Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study. [2005.08]
Effect of terazosin on tissue vascularity and apoptosis in transitional cell carcinoma of bladder. [2005.05]
Terazosin in the treatment of premature ejaculation: a short-term follow-up. [2005]
Effects of alpha-1 adrenergic receptor antagonist, terazosin, on cardiovascular functions in anaesthetised dogs. [2004.12]
Baroreceptor mediated blood pressure regulation is not affected during dose dependent inhibition of prostatic contractions by terazosin. [2004.10]
Cost-effectiveness of tamsulosin, doxazosin, and terazosin in the treatment of benign prostatic hyperplasia. [2004.09]
Immobility from administration of the alpha1-adrenergic antagonist, terazosin, in the IVth ventricle in rats. [2003.12.26]
The alpha1-adrenoceptor antagonist terazosin induces prostate cancer cell death through a p53 and Rb independent pathway. [2003.09]
Effects of intravenous and infravesical administration of suramin, terazosin and BMY 7378 on bladder instability in conscious rats with bladder outlet obstruction. [2003.07]
Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance. [2003.04]
Effect of terazosin on clinical benign prostatic hyperplasia in older adults. [2003.03]
Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia. [2002.06]
Terazosin for benign prostatic hyperplasia. [2002]
Terazosin, doxazosin, and prazosin: current clinical experience. [2001.12]
Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. [2001.11]
|
